Health
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
WILMINGTON, Del., October 19, 2025--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunoth
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6e8b70ab89061844d9a4a994c00dc9c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPdcXS7zxECxPMp6KKIDsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6e8b70ab89061844d9a4a994c00dc9c7","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CV67SMmz485cdq73wCWhdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6e8b70ab89061844d9a4a994c00dc9c7","width":1024,"height":512}},"lazy":false},{"type":"text","content":"AstraZeneca and Daiichi Sankyo’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death in TROPION-Breast02","length":204,"tagName":"p","attribs":{}},{"type":"text","content":"DATROWAY is the first and only therapy to significantly improve overall survival vs. chemotherapy in this patient population","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., October 19, 2025--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.","length":545,"tagName":"p"},{"type":"text","content":"These late-breaking results will be presented today during a Proffered Paper session at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany (abstract #LBA21).","length":188,"tagName":"p"},{"type":"text","content":"DATROWAY demonstrated a 5.0-month improvement in median OS compared to chemotherapy (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.64-0.98; p=0.0291). Median OS was 23.7 months for patients treated with DATROWAY versus 18.7 months for those treated with chemotherapy.","length":276,"tagName":"p"},{"type":"...